175 related articles for article (PubMed ID: 22925970)
1. Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.
McAlearney AS; Song PH; Reiter KL
Contemp Clin Trials; 2012 Nov; 33(6):1143-9. PubMed ID: 22925970
[TBL] [Abstract][Full Text] [Related]
2. Challenges and facilitators of community clinical oncology program participation: a qualitative study.
McAlearney AS; Reiter KL; Weiner BJ; Minasian L; Song PH
J Healthc Manag; 2013; 58(1):29-44; discussion 45-6. PubMed ID: 23424817
[TBL] [Abstract][Full Text] [Related]
3. Implementing community-based provider participation in research: an empirical study.
Teal R; Bergmire DM; Johnston M; Weiner BJ
Implement Sci; 2012 May; 7():41. PubMed ID: 22568935
[TBL] [Abstract][Full Text] [Related]
4. A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.
Reiter KL; Song PH; Minasian L; Good M; Weiner BJ; McAlearney AS
Cancer; 2012 Sep; 118(17):4253-61. PubMed ID: 22213241
[TBL] [Abstract][Full Text] [Related]
5. Organizational and physician factors associated with patient enrollment in cancer clinical trials.
Jacobs SR; Weiner BJ; Reeve BB; Weinberger M; Minasian LM; Good MJ
Clin Trials; 2014 Oct; 11(5):565-75. PubMed ID: 24902923
[TBL] [Abstract][Full Text] [Related]
6. The business case for provider participation in clinical trials research: an application to the National Cancer Institute's community clinical oncology program.
Song PH; Reiter KL; Weiner BJ; Minasian L; McAlearney AS
Health Care Manage Rev; 2013; 38(4):284-94. PubMed ID: 23044836
[TBL] [Abstract][Full Text] [Related]
7. Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.
Carpenter WR; Fortune-Greeley AK; Zullig LL; Lee SY; Weiner BJ
Contemp Clin Trials; 2012 Jan; 33(1):46-54. PubMed ID: 21986391
[TBL] [Abstract][Full Text] [Related]
8. Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.
Penn DC; Chang Y; Meyer AM; DeFilippo Mack C; Sanoff HK; Stitzenberg KB; Carpenter WR
Cancer; 2015 Jan; 121(1):93-101. PubMed ID: 25209056
[TBL] [Abstract][Full Text] [Related]
9. Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.
Weiner BJ; Jacobs SR; Minasian LM; Good MJ
J Oncol Pract; 2012 Sep; 8(5):287-91. PubMed ID: 23277765
[TBL] [Abstract][Full Text] [Related]
10. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
Tan HJ; Meyer AM; Kuo TM; Smith AB; Wheeler SB; Carpenter WR; Nielsen ME
Cancer; 2015 Mar; 121(6):836-43. PubMed ID: 25410684
[TBL] [Abstract][Full Text] [Related]
11. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.
Jacobs SR; Weiner BJ; Minasian LM; Good MJ
Contemp Clin Trials; 2013 Mar; 34(2):320-5. PubMed ID: 23295315
[TBL] [Abstract][Full Text] [Related]
12. Determining the predictors of innovation implementation in healthcare: a quantitative analysis of implementation effectiveness.
Jacobs SR; Weiner BJ; Reeve BB; Hofmann DA; Christian M; Weinberger M
BMC Health Serv Res; 2015 Jan; 15():6. PubMed ID: 25608564
[TBL] [Abstract][Full Text] [Related]
13. Reforming the community research program: from Community Clinical Oncology Program to the National Cancer Institute Community Oncology Research Program.
Zon RT
Am Soc Clin Oncol Educ Book; 2014; ():e116-9. PubMed ID: 24857089
[TBL] [Abstract][Full Text] [Related]
14. Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program.
Kaluzny AD; Ricketts T; Warnecke R; Ford L; Morrissey J; Gillings D; Sondik EJ; Ozer H; Goldman J
J Natl Cancer Inst; 1989 Nov; 81(22):1717-25. PubMed ID: 2681795
[TBL] [Abstract][Full Text] [Related]
15. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.
Kaluzny A; Brawley O; Garson-Angert D; Shaw J; Godley P; Warnecke R; Ford L
J Natl Cancer Inst; 1993 Dec; 85(23):1945-50. PubMed ID: 8230286
[TBL] [Abstract][Full Text] [Related]
16. Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program.
Roth ME; O'Mara AM; Seibel NL; Dickens DS; Langevin AM; Pollock BH; Freyer DR
J Oncol Pract; 2016 Apr; 12(4):e388-95. PubMed ID: 27026648
[TBL] [Abstract][Full Text] [Related]
17. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
Carpenter WR; Meyer AM; Wu Y; Qaqish B; Sanoff HK; Goldberg RM; Weiner BJ
Med Care; 2012 Aug; 50(8):737-48. PubMed ID: 22437624
[TBL] [Abstract][Full Text] [Related]
18. Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program.
Kaluzny AD; Lacey LM; Warnecke R; Hynes DM; Morrissey J; Ford L; Sondik E
Health Serv Res; 1993 Jun; 28(2):159-82. PubMed ID: 8514498
[TBL] [Abstract][Full Text] [Related]
19. The NCI Community Oncology Research Program: what every clinician needs to know.
McCaskill-Stevens W; Lyss AP; Good M; Marsland T; Lilenbaum R
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714464
[TBL] [Abstract][Full Text] [Related]
20. Performance in quasi-firms: an example from the Community Clinical Oncology Program.
Lacey LM; Hynes DM; Kaluzny AD
J Health Hum Resour Adm; 1992; 14(3):307-26. PubMed ID: 10118501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
